A process for making an intraocular implant, the process comprising the steps of: (a) combining: (i) a prostaglandin analog, wherein the prostaglandin analog comprises from about 5% to about 30% by weight of the implant; (ii) a poly(lactide-co-glycolide) copolymer, wherein the poly(lactide-co-glycolide) comprises from about 30% to about 90% by weight of the implant. and; (iii) a second biodegradable polymer to form a mixture, wherein the second biodegradable polymer comprises from about 5% to about 40% by weight of the implant, and wherein; (α) the a poly(lactide-co-glycolide) copolymer and the second biodegradable polymer are different polymers; (β) the solubilities of the prostaglandin analog, the poly(lactide-co-glycolide) copolymer, and the second biodegradable polymer are all within about 10 Mpa 1/2 of each other, and; (γ) the melt temperature of the second biodegradable polymer is lower than the melting point of the a poly(lactide-co-glycolide) copolymer, (b) heating the mixture to the lower melt temperature of the second biodegradable polymer, so that the second biodegradable polymer can function as a solvent for the prostaglandin analog and for the a poly(lactide-co-glycolide) copolymer, and; (c) extruding the heated mixture, thereby making an implant suitable for intraocular use. (a) combining: (i) a prostaglandin analog, wherein the prostaglandin analog comprises from about 5% to about 30% by weight of the implant; (ii) a poly(lactide-co-glycolide) copolymer, wherein the poly(lactide-co-glycolide) comprises from about 30% to about 90% by weight of the implant. and; (iii) a second biodegradable polymer to form a mixture, wherein the second biodegradable polymer comprises from about 5% to about 40% by weight of the implant, and wherein; (α) the a poly(lactide-co-glycolide) copolymer and the second biodegradable polymer are different polymers; (β) the solubilities of the prostaglandin analog, the poly(lactide-co-glycolide) copolymer, and the second biodegradable polymer are all within about 10 Mpa 1/2 of each other, and; (γ) the melt temperature of the second biodegradable polymer is lower than the melting point of the a poly(lactide-co-glycolide) copolymer, (i) a prostaglandin analog, wherein the prostaglandin analog comprises from about 5% to about 30% by weight of the implant; (ii) a poly(lactide-co-glycolide) copolymer, wherein the poly(lactide-co-glycolide) comprises from about 30% to about 90% by weight of the implant. and; (iii) a second biodegradable polymer to form a mixture, wherein the second biodegradable polymer comprises from about 5% to about 40% by weight of the implant, and wherein; (α) the a poly(lactide-co-glycolide) copolymer and the second biodegradable polymer are different polymers; (β) the solubilities of the prostaglandin analog, the poly(lactide-co-glycolide) copolymer, and the second biodegradable polymer are all within about 10 Mpa 1/2 of each other, and; (γ) the melt temperature of the second biodegradable polymer is lower than the melting point of the a poly(lactide-co-glycolide) copolymer, (α) the a poly(lactide-co-glycolide) copolymer and the second biodegradable polymer are different polymers; (β) the solubilities of the prostaglandin analog, the poly(lactide-co-glycolide) copolymer, and the second biodegradable polymer are all within about 10 Mpa 1/2 of each other, and; (γ) the melt temperature of the second biodegradable polymer is lower than the melting point of the a poly(lactide-co-glycolide) copolymer, (b) heating the mixture to the lower melt temperature of the second biodegradable polymer, so that the second biodegradable polymer can function as a solvent for the prostaglandin analog and for the a poly(lactide-co-glycolide) copolymer, and; (c) extruding the heated mixture, thereby making an implant suitable for intraocular use. <EOS>